Gülker H, Heuer H, Thale J, Behrenbeck T
Medizinische Klinik und Poliklinik, Abteilung Innere Medizin C, Westfälische Wilhelms-Universität Münster.
Z Kardiol. 1987 Jul;76(7):411-4.
Diprafenone is a new antiarrhythmic agent currently under clinical investigation, with close chemical similarity to propafenone. In this study, the electrophysiological and haemodynamic effects of the compound were investigated both in animals, by experiment, and in man. Diprafenone produces a dose-dependent prolongation of conduction in all parts of the conducting system. Lengthening of PQ-time is more pronounced than prolongation of QRS. The atrial and ventricular refractory periods are also significantly prolonged. There are no significant changes in the QT-time. Heart rate and aortic pressure are slightly decreased. The electrophysiological and haemodynamic profile of Diprafenone is similar to propafenone with respect to a dominant local anaesthetic activity and an additional beta-sympatholytic effect. However, with respect to the dose needed, the efficacy of the new drug appears to be significantly stronger. Diprafenone can be considered an effective antiarrhythmic drug for the treatment of supraventricular and ventricular tachyarrhythmias.
双苯丙胺是一种目前正在进行临床研究的新型抗心律失常药物，其化学结构与普罗帕酮极为相似。在本研究中，通过实验对该化合物在动物和人体中的电生理及血流动力学效应进行了研究。双苯丙胺可使传导系统各部位的传导时间呈剂量依赖性延长。PQ间期的延长比QRS间期的延长更为显著。心房和心室的不应期也显著延长。QT间期无明显变化。心率和主动脉压略有下降。就主要的局部麻醉活性和额外的β-交感神经阻滞作用而言，双苯丙胺的电生理和血流动力学特征与普罗帕酮相似。然而，就所需剂量而言，新药的疗效似乎明显更强。双苯丙胺可被视为治疗室上性和室性快速性心律失常的有效抗心律失常药物。
